Patricia Nell Hurter

This inventor holds 16 USPTO granted patents and 14 published patent applications, plus 2 CIPO patents and 9 EPO patents. Top assignee: Vertex Pharmaceuticals, Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Patricia Nell Hurter. Retrieved from https://idiyas.com/inventor/patricia-nell-hurter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 14)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 9 (Patent Applications = 8)

Average Co-Inventor Count = 9.4

ph-index = 10

Forward Citations = 491(Granted Patents)

Company Filing History:

16 out of 1,167

Vertex Pharmaceuticals, Inc.

patents

Years Active: 2013-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12458635 - Pharmaceutical composition and administrations thereof (2025-11-04),

2. 12214083 - Pharmaceutical composition and administrations thereof (2025-02-04),

3. 11752106 - Pharmaceutical composition and administrations thereof (2023-09-12),

4. 11564916 - Pharmaceutical composition and administrations thereof (2023-01-31),

5. 11291662 - Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (2022-04-05),

6. 11147770 - Pharmaceutical composition and administrations thereof (2021-10-19),

7. 10646481 - Pharmaceutical composition and administrations thereof (2020-05-12),

8. 10537565 - Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (2020-01-21),

9. 10272046 - Pharmaceutical composition and administrations thereof (2019-04-30),

10. 10231932 - Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases (2019-03-19),

11. 9931334 - Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (2018-04-03),

12. 9670163 - Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (2017-06-06),

13. 9139530 - Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (2015-09-22),

14. 8883206 - Pharmaceutical composition and administrations thereof (2014-11-11),

15. 8754224 - Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (2014-06-17),

Title: The Innovative Inventor: Patricia Nell Hurter

Introduction:

Patricia Nell Hurter is a prolific inventor based in Harvard, MA, with a remarkable track record of 14 patents to her name. Her groundbreaking work in pharmaceutical compositions has pushed the boundaries of treatment options for various medical conditions.

Latest Patents:

Hurter's latest patents focus on pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide. These formulations have paved the way for innovative methods of treating cystic fibrosis, showcasing her dedication to advancing healthcare solutions.

Career Highlights:

Currently employed at Vertex Pharmaceuticals, Inc., Hurter continues to drive innovation in the pharmaceutical industry. Her expertise in formulating solid dispersions has revolutionized drug delivery mechanisms, making treatments more effective and accessible to patients in need.

Collaborations:

Hurter's collaborative spirit is evident through her work with esteemed colleagues such as William Rowe and Christopher Young. Together, they have contributed to the development of cutting-edge pharmaceutical compositions, setting new standards for medical advancements.

Conclusion:

In conclusion, Patricia Nell Hurter stands as a trailblazing inventor whose ingenuity and commitment to improving healthcare have left a lasting impact on the industry. With 14 patents under her belt and a drive for innovation, she continues to inspire future generations of inventors in the pursuit of groundbreaking discoveries.

Profile summary based on public USPTO records.